Hormone receptor positive breast cancer

• SIE-1 Recruiting
  2025-523269-31-00 3 2026-06-02 "Hormone receptor-positive early breast cancer in post-menopa"
• Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing adjuvant Elacestrant with standard endocrine treatment in genomically and/ … Recruiting
  2025-522484-15-00 5 2026-04-27 "ER+/HER2- early breast cancer"
• PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CAMIZESTRANT PLUS RIBOCICLIB IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE (HR+) BREAST C … Recruiting
  2024-520027-88-00 4 2026-02-12 "Patients with hormone receptor-positive (HR+) breast cancer"
• An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy versus Treatment of Physician’s Choice in Hormone Rec … Recruiting
  2025-520582-51-00 5 2025-10-17
• Clinical trial that compares MK-2870 with or without pembrolizumab to chemotherapy in people with breast cancer that cannot be surgically re … Recruiting
  2023-504918-29-00 5 2024-08-22
• A clinical study to evaluate the safety, efficacy, and impact on quality of life of capivasertib alongside routine endocrine treatment in pa … Recruiting
  2024-511392-15-00 5 2025-11-20 "HR+/HER2- advanced breast cancer"
• The RED FLASH study Recruiting
  2023-507847-13-00 5 2024-08-09 "Breast cancer"
• A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CD … Recruiting
  2023-506888-34-00 1 2024-05-22 "Advanced or metastatic solid tumors including hormone recept"
• CAPTOR-BC: COMPREHENSIVE ANALYSIS OF SPATIAL, TEMPORAL AND MOLECULAR PATTERNS OF RIBOCICLIB EFFICACY AND RESISTANCE IN ADVANCED BREAST CANCE … Recruiting
  2022-500764-35-00 6 2022-10-13 "Patients with advanced HER2-negative, hormone receptor posit"
• Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With HR+/HER2− Metastatic Breast Cancer Who Have Received … Recruitment ended
  2022-502593-17-00 5 2023-09-19 "Locally advanced or metastatic hormone receptor (HR)-positiv"
• A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Versus Alpelisib Plus Fulvestrant in Patients with Hormone Recepto … Recruitment ended
  2022-502322-41-00 5 2023-09-12 "Metastatic breast cancer"
• Phase 3 Clinical Trial of Gedatolisib in Patients with HR Positive, HER2 Negative Advanced or Metastatic Breast Cancer (VIKTORIA-1) Recruitment ended
  2022-502145-10-00 5 2023-06-06 "Hormone Receptor (HR)-Positive, Human Epidermal Growth Facto"
• Phase II study to evaluate diarrhoea discontinuations at 3 cycles in patients with early-stage HER2 positive, hormone receptor positive brea … Recruitment ended
  2024-514630-21-00 4 2022-08-11 "HER2 positive (HER2+), Hormone Receptor positive (HR+) Early"
• A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with I … Recruitment ended
  2024-515617-18-00 1 2022-02-14 "Advanced clear cell renal cell carcinoma (ccRCC), non-clear "
• A randomized, controlled, open-label, phase III-trial on Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing abemaciclib combi … Recruitment ended
  2023-509242-35-00 5 2020-07-23 "HR+/HER2- early breast cancer"
• Palbociclib for HR positive Isolated Local or Regional Recurrence of Breast Cancer Recruitment ended
  2024-510776-20-00 5 2019-10-25 "Female or male patients with histologically confirmed HR-pos"
• Neo-adjuvant chemotherapy combined with Stereotactic Body Radiotherapy to the primary tumour +/- durvalumab (MEDI4736), +/- oleclumab (MEDI9 … Recruitment ended
  2024-511849-19-00 4 2019-10-17 "Luminal B Breast Cancer"
• Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk … Recruitment ended
  2024-515769-32-00 5 2019-07-02 "HR+/HER2- early breast cancer"
• Impact of 18F-FES TEP on therapeutical management in patients with metastatic breast cancer, ER positive and HER2 negative, in relapse after … Ended
  2024-517400-11-00 6 2024-10-24 "Patients with metastatic breast cancer initially presenting "
• A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3 … Ended
  2023-505322-34-00 1 2024-01-08 "Advanced or metastatic solid tumors"
• A dose-escalation and expansion study of the safety and pharmacokinetics of XB002 as single-agent and combination therapy in subjects with i … Ended
  2023-508267-69-00 3 2023-08-11 "Subjects with Aadvanced solid tumors for whom life-prolongin"
• A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK08 , an IL-15 Antibody Fusion Protein Targeting CTLA-4, Mo … Ended
  2024-511750-53-00 7 2022-09-08 "Unresectable Locally Advanced or Metastatic Cancer"
• A Phase 1/2, Open-label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Fadraciclib (CYC065), an Oral CDK2/9 … Ended
  2024-516289-12-00 9 2022-02-24 "Endometrial cancer, Ovarian cancer, Biliary tract cancer, He"

Showing 1–23 of 23 trials